These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 16986231

  • 1. Use of valsartan in post-myocardial infarction and heart failure patients.
    Liu PP, Maggioni A, Velazquez EJ.
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S19-22. PubMed ID: 16986231
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M, Petrescu L, Riviş AI, Suşan RM, Burghină D, Dan R, Cozma D, Drăgulescu SI.
    Rom J Intern Med; 2005 Oct; 43(3-4):187-98. PubMed ID: 16812979
    [Abstract] [Full Text] [Related]

  • 4. Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?
    Pfeffer MA.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S41-3. PubMed ID: 17199221
    [Abstract] [Full Text] [Related]

  • 5. Valsartan in the treatment of heart attack survivors.
    Jugdutt BI.
    Vasc Health Risk Manag; 2006 Jun; 2(2):125-38. PubMed ID: 17319456
    [Abstract] [Full Text] [Related]

  • 6. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 7. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
    Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM.
    Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
    [Abstract] [Full Text] [Related]

  • 8. ACE inhibitors in heart failure: what more do we need to know?
    Demers C, Mody A, Teo KK, McKelvie RS.
    Am J Cardiovasc Drugs; 2005 Dec; 5(6):351-9. PubMed ID: 16259523
    [Abstract] [Full Text] [Related]

  • 9. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 10. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA.
    Circulation; 2005 Jun 28; 111(25):3411-9. PubMed ID: 15967846
    [Abstract] [Full Text] [Related]

  • 11. Rationale for angiotensin II receptor blocker therapy in chronic heart failure.
    Cohn JN.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun 28; 1(2 Suppl):S38-40. PubMed ID: 17199220
    [Abstract] [Full Text] [Related]

  • 12. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 28; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 13. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, van Gilst WH, Zannad F, McMurray JJ, Califf RM, Pfeffer MA, VALIANT Investigators.
    Circulation; 2005 Nov 29; 112(22):3391-9. PubMed ID: 16301343
    [Abstract] [Full Text] [Related]

  • 14. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, VALIANT Investigators.
    Am Heart J; 2005 Aug 29; 150(2):323-9. PubMed ID: 16086938
    [Abstract] [Full Text] [Related]

  • 15. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 16. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.
    Dzau V.
    J Hypertens Suppl; 2005 Apr 20; 23(1):S9-17. PubMed ID: 15821452
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar 20; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
    Epstein BJ, Gums JG.
    Ann Pharmacother; 2005 Mar 20; 39(3):470-80. PubMed ID: 15701766
    [Abstract] [Full Text] [Related]

  • 19. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Aguilar D, Solomon SD, Køber L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O'Connor CM, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA.
    Circulation; 2004 Sep 21; 110(12):1572-8. PubMed ID: 15364810
    [Abstract] [Full Text] [Related]

  • 20. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA, Movahed A.
    Rev Cardiovasc Med; 2005 Sep 21; 6(4):206-13. PubMed ID: 16379016
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.